Efficacy of swine influenza A virus vaccines against an H3N2 virus variant.
We compared the efficacy of 3 commercial vaccines against swine influenza A virus (SIV) and an experimental homologous vaccine in young pigs that were subsequently challenged with a variant H3N2 SIV, A/Swine/Colorado/00294/2004, selected from a repository of serologically and genetically characterized H3N2 SIV isolates obtained from recent cases of swine respiratory disease. The experimental vaccine was prepared from the challenge virus. Four groups of 8 pigs each were vaccinated intramuscularly at both 4 and 6 wk of age with commercial or homologous vaccine. Two weeks after the 2nd vaccination, those 32 pigs and 8 nonvaccinated pigs were inoculated with the challenge virus by the deep intranasal route. Another 4 pigs served as nonvaccinated, nonchallenged controls. The serum antibody responses differed markedly between groups. After the 1st vaccination, the recipients of the homologous vaccine had hemagglutination inhibition (HI) titers of 1:640 to 1:2560 against the challenge (homologous) virus. In contrast, even after 2nd vaccination, the commercial-vaccine recipients had low titers or no detectable antibody against the challenge (heterologous) virus. After the 2nd vaccination, all the groups had high titers of antibody to the reference H3N2 virus A/Swine/Texas/4199-2/98. Vaccination reduced clinical signs and lung lesion scores; however, virus was isolated 1 to 5 d after challenge from the nasal swabs of most of the pigs vaccinated with a commercial product but from none of the pigs vaccinated with the experimental product. The efficacy of the commercial vaccines may need to be improved to provide sufficient protection against emerging H3N2 variants.
Lee
Jee Hoon
JH
Department of Veterinary Population Medicine, College of Veterinary Medicine, University of Minnesota, 385 Animal Science/Veterinary Medicine Building, 1988 Fitch Avenue, St. Paul, Minnesota 55108, USA.
Gramer
Marie René
MR
Joo
Han Soo
HS
D000818:Animals; D000914:Antibodies, Viral / Q000097:blood*; D006385:Hemagglutination Inhibition Tests / Q000662:veterinary; D007114:Immunization / Q000662:veterinary; D053122:Influenza A Virus, H3N2 Subtype / Q000276:immunology*; D007252:Influenza Vaccines / Q000276:immunology*; D007273:Injections, Intramuscular / Q000662:veterinary; D009296:Nasal Cavity; D009976:Orthomyxoviridae Infections / Q000517:prevention & control / Q000662:veterinary*; D011897:Random Allocation; D013552:Swine; D013553:Swine Diseases / Q000517:prevention & control*
D000914:Antibodies, Viral; D007252:Influenza Vaccines
Arch Virol. 1991;116(1-4):261-5
1848066
Vet Pathol. 1995 Nov;32(6):648-60
8592800
Can J Vet Res. 1996 Oct;60(4):312-4
8904668
Vet Microbiol. 2000 May 22;74(1-2):47-58
10799777
Virus Res. 2000 Jun;68(1):71-85
10930664
J Virol. 2000 Sep;74(18):8243-51
10954521
Arch Virol. 2000;145(7):1399-419
10963345
Vaccine. 2001 Aug 14;19(31):4479-86
11483274
Vet Immunol Immunopathol. 2001 Sep 28;82(1-2):39-56
11557293
J Clin Microbiol. 2002 Mar;40(3):1073-9
11880444
J Virol Methods. 2002 Apr;102(1-2):53-9
11879692
J Vet Diagn Invest. 2002 Mar;14(2):169-71
11939342
Virus Res. 2002 May 10;85(2):199-210
12034486
Vaccine. 2003 Mar 28;21(13-14):1375-81
12615433
J Clin Microbiol. 2003 Jul;41(7):3198-205
12843064
Can Vet J. 2003 Sep;44(9):735-7
14524628
Virus Res. 2004 Jul;103(1-2):67-73
15163491
Vaccine. 2004 Sep 3;22(25-26):3427-34
15308368
J Clin Microbiol. 1979 Feb;9(2):175-9
219021